Research from the Hebrew University published in Molecular Psychiatry shows psilocybin can significantly decrease OCD-like ...

A new study published in the journal Molecular Psychiatry suggests possible benefits of using psilocybin-containing mushroom extract over its chemically synthesized counterpart for the treatment ...

The paper is titled "Striking Long Term Beneficial Effects of Single Dose Psilocybin and Psychedelic Mushroom Extract in the SAPAP3 Rodent Model of OCD-Like Excessive Self-Grooming." The research ...

The matchup: Two doses of psilocybin, the active ingredient in “magic mushrooms,” against a six-week course of the popular antidepressant escitalopram, often sold as Lexapro or Cipralex.

The company will provide Mātai with its GMP Full Spectrum Natural Psilocybin extract, and further track stability of the extract toward ensuring the highest standards of GMP quality and compliance.

Research conducted on mice showed that psilocybin and psychedelic mushroom extract significantly reduced OCD-like behaviors and tic-like head-body twitches. These promising results pave the way ...

The researchers did not provide any psilocybin mushrooms to participants, but observed and recorded the participants’ experiences as they were engaging in their own “Microdose practice.” ...

Psychedelic drug psilocybin, found in magic mushrooms, is as good at reducing symptoms of depression as conventional treatment, a small, early-stage study has suggested. But when it comes to ...